Guide to Chiome Bioscience

Guide to Chiome Bioscience

  • 1. Chiome’s Goal
  • 2. Contributing to Antibody Drugs and Antibody Drug Discovery
  • 3. Strengths of the ADLib® System
  • 4. Business Model
  • 5. Chiome’s Potential by Numbers

The ADLib® system technology, a product of Japan’s RIKEN institute, has been patented worldwide.
The ADLib® system creates antibodies with revolutionary speed and diversity.

The ADLib® system has obtained patents in major countries. The internationally respected scientific journal Nature Biotechnology introduced the ADLib® system as “an innovative rapid antibody generating technology that is the first to employ promotion of DNA recombination.” The ADLib® system, which greatly shortens the value chain from drug discovery to production, is a completely different technology from conventional antibody generation techniques (mouse hybridoma method and phage display method). The ADLib® system has the following advantages.

Advantages of the Technology

Antibody Diversity

Animals, including humans, do not produce antibodies against the proteins that comprise their own bodies. As a result, it is extremely difficult to generate antibodies against such protein with the mouse hybridoma method, which uses mice. The extent of variation possible with the phage display method is limited for technical reasons, and it is difficult to obtain high-quality antibodies rapidly with that method.

In contrast, the ADLib® system uses the body’s own unique diversification mechanism, a mechanism also possessed by DT40 cells. Antibody diversity is therefore not limited by immunological tolerance, which is an issue with the mouse hybridoma method. The ADLib® system also overcomes the problems of the phage display method—poor variety in the libraries and the difficulty of assuring quality.

• Comparison with conventional antibody generation technologies (Source: Chiome Bioscience Inc.)

Mouse hybridoma method Phage display method
  • A technology developed more than 30 years ago, antibodies are generated by injecting the target antigen into mice.
  • Since actual animals are used, the number of target antigens that can be used is limited.

  • A virus (phage) infecting E. coli expresses a diverse array of antibodies (only a certain portion of each antibody is expressed).
  • The above diverse array of phages is placed in the wells of a plate with immobilized antigen, and antibodies binding strongly to the antigen are collected.
  • A portion of the desired antibody can be acquired by analyzing the genes of the phages obtained.

Revolutionary Speed (About 10 Days) and Success Rate

The ADLib® system greatly reduces the discovery time for antibodies used to make drugs. It is not dependent on the in vivo immune function, and the system provides monoclonal antibodies in vitro in 10 days, in the fastest case. The ADLib® system dramatically reduces development time and development costs, compared to conventional small-molecule drugs.

• Antibody generation time: ADLib® system versus competing techniques (source: Chiome Bioscience Inc.)

Provides Antibodies against a Variety of Tough Antigens

The ADLib® system can generate a diverse array of antibodies against antigens for which antibodies were difficult to obtain with conventional methods (e.g., specific antibodies against pathogenic toxins, pathogens, and self-antibodies).

Chiome Bioscience Inc. has developed the ADLib® axCELL, a practical application of the ADLib® system. We successfully obtained an antibody to a seven-transmembrane protein (GPCR), an antigen that is the drug target of highest interest at this time.

• Schematic of ADLib® axCELL Process (Generation of antibodies against multiple transmembrane proteins by cell selection)

• Advantages of the ADLib® System
  ADLib® System Mouse hybridoma method Phage display method
Facilities Normally equipped lab Requires animal facility Requires facilities for recombinant DNA experiments
Diversity Potentially infinite Limited Limited
Antibody generation time Around 10 days About 6 months 2.5 to 3.5 months
Tough antigens Applicable Applicable to some Applicable to some

Patents and Awards

Basic patents have been granted for the ADLib® system in major countries

Chiome Bioscience Inc. completed registration of basic patents for the ADLib® system in China in 2007, Japan in 2008, and the U.S. and Europe in 2010. In addition, Chiome Bioscience has filed related patents inside and outside of Japan on a timely basis. Chiome Bioscience has established a system for exclusively commercializing the ADLib® system technology.

  • • Title of the invention: Method of Enhancing Homologous Recombination of Somatic Cells and Method of Constructing Specific Antibody
  • • Chiome Bioscience and RIKEN each hold 50% of the patent rights

Technology described in the internationally respected journal Nature Biotechnology

The internationally respected scientific journal Nature Biotechnology introduced the ADLib® system as “an innovative rapid antibody generating technology that is the first to employ promotion of DNA recombination.” The system has won numerous awards, including the Invitrogen-Nature Biotechnology Award (Venture division) (May 2006), Excellence Award at the Tokyo Venture Technology Awards (October 2006), the Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology (April 2007), and the Japan Bio-Venture Award from the Minister of Education, Culture, Sports, Science and Technology (October 2009). Chiome Bioscience Inc. has been selected to receive support from and do contract work for NEDO (the New Energy and Industrial Technology Development Organization).